Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Terbutaline sulphate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bricanyl Turbuhaler M2, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation |
| Bricanyl Turbuhaler M3, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation |
| Turbuhaler M2, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Turbuhaler M3, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Name | Type | Description |
|---|---|---|
| Terbutaline sulphate | DRUG | Bricanyl Turbuhaler M2 |
| Placebo for terbutaline sulphate | DRUG | Placebo Turbuhaler M2 |
Inclusion Criteria: - Female and male aged 18 and 65 years. * At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1 * Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide cor...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Terbutaline sulphate is used for the treatment of asthma. It is a small molecule bronchodilator developed by AstraZeneca PLC. The drug has been studied in a Phase 3 clinical trial in adults with asthma, and it is delivered via inhalation using the Bricanyl Turbuhaler device.
Terbutaline sulphate works as an agonist at the beta-2 adrenergic receptor, also known as ADRB2. By activating this receptor, it relaxes the smooth muscle in the airways, which helps to open them and relieve asthma symptoms. This makes it a bronchodilator.
Terbutaline sulphate is made by AstraZeneca PLC, which trades under the ticker symbol AZN. AstraZeneca is the developer of the drug and the Bricanyl Turbuhaler delivery device.
Terbutaline sulphate is in Phase 3 clinical development for asthma. It is an investigational product and has not been approved by the FDA for this specific use. The Phase 3 trial has been completed.
Terbutaline sulphate has been studied in a completed Phase 3 trial, NCT02322788. This trial compared Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels in 95 adults with asthma. It was randomized, double-blind, and placebo-controlled, and took place in Canada, the Netherlands, and Sweden.
Yes, terbutaline sulphate is the active ingredient in Bricanyl, a brand name for the drug. Bricanyl is available in a Turbuhaler device, and the clinical trial NCT02322788 compared different versions of the Bricanyl Turbuhaler.